Oncotelic Therapeutics, Inc.
BiotechnologyImmuno-Oncology & Virology RNA Therapeutics
Agoura Hills, CA
About
Oncotelic Therapeutics, Inc. is a publicly traded, clinical-stage biotechnology company developing RNA therapeutics and small-molecule drugs for immuno-oncology and virology. The company's primary focus is on advancing its lead candidate, OT-101, which targets the TGF-β pathway to treat solid tumors and severe viral diseases. Oncotelic also leverages a proprietary AI platform to support its research and development efforts.
Company Values
The company's strategy integrates a first-in-class TGF-β antisense RNA therapeutic (OT-101) with an AI-augmented research platform (PDAOAI) to accelerate the development of precision oncology treatments.